Literature DB >> 36563

Cyclophosphamide therapy of severe systemic necrotizing vasculitis.

A S Fauci, P Katz, B F Haynes, S M Wolff.   

Abstract

We studied 17 patients with severe systemic necrotizing vasculitis over an 11-year-period. Sixteen patients were treated daily with cyclophosphamide (2 mg per kilogram per day), and one was treated with azathioprine (2 mg per kilogram per day). Before entering the study, all patients had active and progressive disease, even though 16 patients had been receiving corticosteroids that had caused severe and often incapacitating toxic side effects. Three patients died during the study. Complete and often dramatic remissions occurred in the surviving 14 patients, who were then placed on alternate-day corticosteroid treatment with continuation of cyclophosphamide. Corticosteroids were later discontinued in seven patients. The mean duration of remission was 22 months (range, two to 61). No patient showed recurrence of disease during treatment with cytotoxic agents.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 36563     DOI: 10.1056/NEJM197908023010503

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  68 in total

Review 1.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Clinical management and treatment of vasculitis.

Authors:  D Jayne
Journal:  Springer Semin Immunopathol       Date:  2001

Review 3.  The use of immunosuppressive and cytotoxic drugs in non-malignant disease.

Authors:  P A Brogan; M J Dillon
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

Review 4.  Treatment of ANCA-associated vasculitis, where to go?

Authors:  Cees G M Kallenberg
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 5.  Vasculitis in children.

Authors:  L Kumar; S Singh
Journal:  Indian J Pediatr       Date:  1996 May-Jun       Impact factor: 1.967

6.  ELISA is the superior method for detecting antineutrophil cytoplasmic antibodies in the diagnosis of systemic necrotising vasculitis.

Authors:  A Harris; G Chang; M Vadas; D Gillis
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

7.  Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Authors:  David R W Jayne; Annette N Bruchfeld; Lorraine Harper; Matthias Schaier; Michael C Venning; Patrick Hamilton; Volker Burst; Franziska Grundmann; Michel Jadoul; István Szombati; Vladimír Tesař; Mårten Segelmark; Antonia Potarca; Thomas J Schall; Pirow Bekker
Journal:  J Am Soc Nephrol       Date:  2017-04-11       Impact factor: 10.121

8.  [A patient with Churg-Strauss syndrome presenting as Guillain-Barré syndrome].

Authors:  M Djukic; H Schmidt; C Mazurek; F König; S Schweyer; R Nau
Journal:  Nervenarzt       Date:  2008-04       Impact factor: 1.214

9.  Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases.

Authors:  P Hollingworth; A de Vere Tyndall; B M Ansell; T Platts-Mills; J M Gumpel; J Mertin; D S Smith; A M Denman
Journal:  Ann Rheum Dis       Date:  1982-12       Impact factor: 19.103

10.  Polyarteritis nodosa: regression of arterial aneurysms following immunosuppressive and corticosteroid therapy.

Authors:  D K Yousefzadeh; K C Chow; C A Benson
Journal:  Pediatr Radiol       Date:  1981-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.